KMT2A and leukemia: Our laboratory worked on a transgenic mouse model where this interaction is abrogated and observed that this transgenic mouse failed to develop leukaemia upon expression of oncogenic fusion proteins such as acute myeloid leukemia-eight-twenty-one (AML-ETO) and MLL-AF9 [29].